Preferred Label : Selpercatinib;
NCIt synonyms : RET Kinase Inhibitor LOXO-292; 6-(2-Hydroxy-2-methylpropoxy)-4-(6-(6-((6-methoxypyridin-3-yl)methyl)-3,6-diazabicyclo(3.1.1)heptan-3-yl)pyridin-3-yl)pyrazolo(1,5-a)pyridine-3-carbonitrile; WHO 10967;
NCIt related terms : RET Inhibitor LOXO-292;
NCIt definition : An orally bioavailable selective inhibitor of wild-type, mutant and fusion products
involving the proto-oncogene receptor tyrosine kinase rearranged during transfection
(RET), with potential antineoplastic activity. Upon oral administration, selpercatinib
selectively binds to and targets wild-type RET as well as various RET mutants and
RET-containing fusion products. This results in an inhibition of cell growth of tumors
cells that exhibit increased RET activity. In addition, selpercatinib targets, binds
to and inhibits vascular endothelial growth factor receptor 1 (VEGFR1) and 3 (VEGFR3),
and fibroblast growth factor receptor 1 (FGFR1), 2 (FGFR2), and 3 (FGFR3). RET overexpression,
activating mutations, and fusions result in the upregulation and/or overactivation
of RET tyrosine kinase activity in various cancer cell types; dysregulation of RET
activity plays a key role in the development and progression of these cancers.;
UNII : CEGM9YBNGD;
InChIKey : XIIOFHFUYBLOLW-UHFFFAOYSA-N;
CAS number : 2152628-33-4;
Drug name : Retevmo; Retsevmo;
Molecule name : LOXO-292; LOXO 292;
NCI Metathesaurus CUI : CL522497;
Codes from synonyms : 13759;
Origin ID : C134987;
UMLS CUI : C5235396;
Automatic exact mappings (from CISMeF team)
- Currated CISMeF NLP mapping
- Semantic type(s)
- UMLS correspondences (same concept)
- concept_is_in_subset
- has_target
- is_component_of_chemotherapy_regimen
